Empowering Next-Generation Oncology Breakthroughs
Since 2018, over $40 million has been granted to support exceptional cancer research projects led by promising early-career scientists. The Mark Foundation for Cancer Research proudly introduces the 2026 Emerging Leader Awards (ELA), recognizing five trailblazing early-career researchers who are set to make impactful contributions in the field of oncology. Each selected investigator will receive a staggering $750,000 over three years to foster innovative ventures that challenge conventional wisdom in the detection, diagnosis, and treatment of cancer.
A Commitment to Support Innovative Science
Ryan Schoenfeld, PhD, CEO of The Mark Foundation, emphasizes the importance of investing in early-career scientists. "Now more than ever, it is vital that we provide robust support to early-career scientists to ensure they have the resources needed to pursue their most ambitious ideas. As governmental funding faces uncertainties, philanthropy must step in to aid these brilliant minds. Today’s investment will enable groundbreaking discoveries tomorrow, paving the way for advancements in cancer treatment," he stated.
Meet the 2026 ELA Recipients
The 2026 ELA recipients are confronting some of the most intricate challenges in oncology. Their research spans a variety of innovative approaches, including:
Jeremy Borniger, PhD, Cold Spring Harbor Laboratory
The Bakewell Emerging Leader Award - Dr. Borniger's project on Synthetic Torpor for Anti-Cancer Therapy explores how inducing a hibernation-like state can suppress tumor metabolism while preserving normal tissues.
Iok In Christine Chio, PhD, Columbia University
Dr. Chio's study titled Systemic Iron Remodeling as an Early Indicator of Pancreatic Cancer focuses on developing advanced imaging methods to detect pancreatic cancer at its earliest phases by observing iron distribution changes in the body.
Lucas Farnung, PhD, Harvard Medical School
Farnung's research, Molecular Mechanisms of DNA Replication and Epigenetic Inheritance, utilizes cutting-edge biochemistry at an atomic scale to understand how DNA replication errors contribute to cancer, identifying new therapeutic targets.
Mariella Filbin, MD, PhD, Dana-Farber Cancer Institute
Dr. Filbin's investigation into Neuronal-Activity-Driven DNA Repair in Diffuse Midline Gliomas examines how aggressive childhood brain tumors exploit normal brain processes to repair DNA, opening doors for overcoming radiation resistance.
Christopher Johnston, PhD, The University of Texas MD Anderson Cancer Center
Johnston's research focuses on Engineering Microbial Cellular Therapies Against Cancer, creating human-derived bacterial strains designed to penetrate solid tumors and deliver therapeutic agents directly where they are needed most.
A Legacy of Impactful Funding
Since its inception in 2018, the Emerging Leader Award program from The Mark Foundation has disbursed over $40 million to promising early-career researchers. This initiative has not only propelled various clinical trials but also sparked the formation of groundbreaking biotechnology firms and shifted our understanding of cancer's fundamental mechanisms.
This year, The Mark Foundation proudly partners with The Bakewell Foundation in support of Dr. Jeremy Borniger's groundbreaking research. The Bakewell Foundation is committed to collaborating with top scientists focused on achieving measurable breakthroughs in oncology. This partnership underscores a shared vision to harness bold and translational science aimed at conquering cancer.
To discover more about the Emerging Leader Award program and the remarkable achievements of the 2026 recipients, please visit themarkfoundation.org and follow @markfdn on X and Bluesky. Connect with The Mark Foundation for Cancer Research on LinkedIn to stay updated.
About The Mark Foundation for Cancer Research
The Mark Foundation for Cancer Research is a charitable organization based in New York City, dedicated to accelerating transformative research in cancer prevention, diagnosis, and therapy worldwide. Since its establishment in 2017, The Mark Foundation has allocated over $300 million in grants across more than 120 academic institutions in 18 countries. Their focus encompasses supporting early career researchers, promoting collaborative science, fostering technology innovation, and discovering new therapeutic methods. Additionally, The Mark Foundation boasts a growing portfolio of investments in burgeoning cancer diagnostics and therapeutic ventures. Learn more by visiting www.themarkfoundation.org.
Frequently Asked Questions
What is the Emerging Leader Award program?
The Emerging Leader Award program supports early-career cancer researchers with significant funding for innovative projects in oncology.
How much funding do the recipients receive?
Each selected recipient of the 2026 ELA will be awarded $750,000 over a three-year period to support their research.
What type of projects do the ELA recipients focus on?
Recipients tackle complex challenges, creating innovative solutions in cancer detection, diagnosis, and therapy.
How long has The Mark Foundation been supporting cancer research?
The Mark Foundation has been active since 2017, contributing over $300 million in grants to advance cancer research globally.
Where can I learn more about The Mark Foundation?
For more information, visit their official website at www.themarkfoundation.org.
